Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
GLYNN et al v. MERCK SHARP & DOHME CORP.
Case Number:
3:11-cv-05304
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
July 02, 2013
Fosamax Ruling Puts Preemption In Play For Branded Drugs
A New Jersey federal judge's ruling Thursday that claims related to Merck & Co. Inc.'s Fosamax are preempted by federal law will likely inspire other brand-name drug makers to mount the defense, which companies have forsaken following an unfavorable U.S. Supreme Court decision four years ago.
-
April 29, 2013
Merck Wins First Femur-Related Fosamax Suit
Merck & Co. on Monday triumphed in a New Jersey bellwether trial over femur fractures allegedly caused by its bone drug Fosamax, after a jury ruled that the nature of the plaintiff's injury ruled out Fosamax as a potential cause.
-
April 11, 2013
Merck Can't Boot Witnesses From Bellwether Fosamax Trial
A New Jersey federal judge on Wednesday denied Merck & Co.'s bid to block the testimony of eight doctors in the first trial over femur fractures allegedly caused by its bone drug Fosamax, but said the plaintiff's treating physicians may not discuss general causation.
-
April 09, 2013
Merck Ignored Fosamax Femur Injury Warnings, Jury Told
Merck & Co. on Tuesday faced its first suit claiming femur fractures were caused by its bone drug Fosamax in New Jersey federal court, with attorneys for a New York woman who sustained a femur break saying Merck ignored warnings of the drug's risks.
-
January 16, 2013
Merck Says Fosamax Femur Fracture Claims Are Preempted
Merck & Co. Inc. urged a New Jersey federal court Tuesday to dismiss part of a multidistrict litigation accusing it of negligence and other claims over femur fractures and similar injuries allegedly caused by its osteoporosis drug Fosamax, arguing those claims are preempted.